Product Description
ACI-7104 is an optimized vaccine formulation designed to induce a-syn-specific antibodies recognizing aggregated a-syn species that are toxic to neurons. (Sourced from: https://www.acimmune.com/pipeline/clinical-trials/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AC Immune
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Spain, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Expected - AC Immune announced they will present P2 Parkinson's Disease results on 2026-03-18 for ACI-7104
- Clinical Outcomes Reported - AC Immune presented P2 Parkinson's Disease results on 2025-12-11 for ACI-7104
- Clinical Outcomes Reported - AC Immune announced they will present P2 Parkinson's Disease results in 4Q25 for ACI-7104
Highest Development Phases
Phase 2: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06015841 |
VacSYn | P2 |
Active, not recruiting |
Parkinson's Disease |
2028-01-01 |
12% |
2025-11-22 |
Primary Endpoints |
2022-500292-31-00 |
ACI-7104-PD-2103 | P2 |
Recruiting |
Parkinson's Disease |
2028-01-31 |
12% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/11/2025 |
News Article |
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease |
|
07/26/2023 |
News Article |
AC Immune SA Appoints New Chief Medical Officer |
|
07/26/2023 |
News Article |
AC Immune SA Appoints New Chief Medical Officer |
|
03/20/2023 |
News Article |
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline |